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http://dx.doi.org/10.1016/j.jacl.2015.0BACKGROUND: Serum high-density lipoprotein cholesterol (HDL-C) has been reported to be lower
in Asians than in Caucasians.
OBJECTIVE: We compared HDL-C levels between the Korean and US populations using stratified
analysis according to age and sex and estimated the optimal cutoff value for HDL-C that best predicts
the risk of cerebrovascular accidents (CVAs) and ischemic heart disease (IHD) in Koreans.
METHODS: The Korean National Health and Nutrition Examination Survey (KNHANES)
2010-2012 and the National Health and Nutrition Examination Survey (NHANES) 2011-2012 were
used for the Korean and US populations, respectively. HDL-C levels were compared using general
linear models. To estimate the optimal HDL-C cutoff value that predicts CVAs and IHD, sensitivity
and specificity of different HDL-C levels were calculated.
RESULTS: The mean HDL-C level was significantly lower in KNHANES in both sexes (46.1 [stan-
dard error, 0.2] mg/dL in KNHANES and 47.7 [0.5] mg/dL in NHANES, P 5 .003 in men, and 51.2
[0.2] mg/dL in KNHANES and 58.3 [0.8] mg/dL in NHANES, P , .001 in women). The optimal
HDL-C cutoff to predict CVA-IHD was 43 mg/dL and 48 mg/dL for Korean men and women, respec-
tively, and 41 mg/dL and 56 mg/dL for US men and women, respectively.
CONCLUSION: HDL-C levels are significantly lower in both sexes in the Korean population than the
US population. The optimal cutoff HDL-C value to predict the risk of CVA-IHD was 43 mg/dL for men
and 48 mg/dL for women in the Korean population.
 2015 National Lipid Association. This is an open access article under the CCBY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).to this work.
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1.009Metabolic syndrome is a condition characterized by the
presence of multiple metabolic risk factors for cardiovas-
cular disease.1 Low levels of high-density lipoprotein
cholesterol (HDL-C), which is a component of metabolic
syndrome, are associated with an elevated risk of athe-
rosclerotic disorders such as cerebrovascular accidentsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/
Moon et al HDL cholesterol cutoff for Koreans 335(CVAs)2 and ischemic heart disease (IHD).3,4 The National
Cholesterol Education Program (NCEP) Adult Treatment
Panel (ATP) III adopted HDL-C levels of ,40 mg/dL in
men and ,50 mg/dL in women to indicate the cutoff for
low HDL-C in metabolic syndrome5 based on epide-
miologic studies conducted in insulin resistant men6 and
women.7,8 However, the inverse association between
HDL-C concentrations and IHD risk is continuous, and a
threshold relationship has not yet been identified.9 Despite
this limitation, this HDL-C cutoff is frequently used to
estimate the risk of several metabolic and cardiovascular
diseases in Korea.10–12
Interestingly, nationwide surveys conducted in the
Korean and US populations have shown that the prevalence
of low HDL-C in the Korean population is significantly
higher than that in the US population, especially in
women.13 In the Korean National Health and Nutrition
Examination Survey (KNHANES) 2001-2007, 59.3% to
61.2% of Korean women had low HDL-C, which was
almost double that of US women (33.8%) in the National
Health and Nutrition Examination Survey (NHANES)
1998-2006.13 However, the incidence of cardiovascular dis-
ease in the Korean population is not higher than that in the
US population.14
Serum HDL-C concentrations differ by ethnicity, with
reportedly lower HDL-C levels in Asians than in Cauca-
sians.15 Furthermore, in the Korean population, the sex dif-
ference in HDL-C levels may not be as significant. On
average, HDL-C levels are 10 mg/dL lower in adult Cauca-
sian men than in Caucasian women9,16; however, the differ-
ence in mean (standard error [SE]) HDL-C levels between
sexes was lower in KNHANES 2005 (43.8 [0.2] and 46.3
[0.2] mg/dL in men and women, respectively).17
Considering the ethnic differences in HDL-C, the
estimation of an adequate cutoff for low HDL-C level to
predict cardiovascular disease in the Korean population is
important for the prevention and management of cardio-
vascular disease. However, there have been few studies to
investigate HDL-C levels for this purpose in the Korean
population. In the present study, we compared HDL-C
levels based on the presence of CVA and IHD between the
Korean and US populations using nationwide surveys
conducted in the early 2010s. In addition, we estimated
the cutoff value for HDL-C that best predicts the risk of
CVA and IHD in the Korean population.Methods
Subjects
The Korean Ministry of Health and Welfare designed the
KNHANES, which has been conducted since 1998, to be
representative of the Korean population using a stratified,
multistage, probability sampling method; the survey has
been described in detail elsewhere.13,18 We analyzed datafrom the KNHANES V, which was conducted from January
2010 to December 2012 with 25,533 individuals (partici-
pation rate, 80.8%), representing 11,400 households and
576 sampling frames.
For the analysis of the US population, the NHANES was
used. It is a cross-sectional, nationwide study conducted by
the Centers for Disease Control and Prevention (CDC) and
is designed to evaluate the health and nutritional status of
the noninstitutionalized US population. Further details are
described elsewhere.19 Data from NHANES 2011-2012
were used for analysis, including 9756 individuals.
Subjects aged $30 years with HDL-C measurement
were included in the analysis. In KNHANES (n 5 25,533),
17,292 (67.7%) subjects were aged $30 years, and serum
HDL-C was measured in 15,074 (87.2% of age $30 years)
subjects. In NHANES (n 5 9756), 4566 (46.8%) subjects
were aged $30 years, and 4033 (88.3% of age $30 years)
measured HDL-C.
Measurement of metabolic parameters and
disease definitions
Anthropometric and laboratory measurements in the
KNHANES were as described in the following. Height
was measured to the nearest 0.1 cm using a stadiometer
(seca 210, seca, Hamburg, Germany), and weight was
measured to the nearest 0.1 kg (GL-6000-20, G-tech,
Uijeongbu City, Korea). Body mass index (BMI) was
calculated as body weight (kg) divided by height squared
(m2). Waist circumference was measured to the nearest
0.1 cm (seca 200, seca). A mercury sphygmomanometer
(Baumanometer, Baum, Copiague, NY, USA) was used to
measure blood pressure to the nearest 2 mm Hg.
Blood samples were drawn from the antecubital vein in
the morning after fasting for at least 8 hours. Samples
were properly processed, immediately refrigerated at 2C
to 8C, and sent to a central laboratory. Total cholesterol,
HDL-C, low-density lipoprotein cholesterol (LDL-C),
triglycerides (TGs), and fasting glucose were measured
enzymatically (Hitachi Automatic Analyzer 7600, Hitachi,
Tokyo, Japan). Glycated hemoglobin was measured by
high-performance liquid chromatography (HLC-723G7,
Tosoh, Tokyo, Japan).
The revised HDL-C value was determined, following
reference values from the Clinical and Laboratory Stan-
dards Institute for metrological traceability. To verify the
accuracy of HDL-C, traceability analysis was conducted by
KNHANES in 2013 to confirm the accuracy of HDL-C
measurement. Difference of HDL-C values from Korean
central laboratory and US CDC were 5.3% to 9.2% for
2008 to 2011, and 2.3% to 3.5% for 2012. For this reason,
new regression formula of HDL-C was necessary to verify
HDL-C value, especially for 2008 to 2011. Commutable
frozen serum samples were taken according to Clinical and
Laboratory Standards Institute guideline, and samples were
sent to CDC. Samples were analyzed with gold-standard
336 Journal of Clinical Lipidology, Vol 9, No 3, June 2015method by isotope dilution-gas chromatography-mass spec-
trometry. Following obtained data from CDC and Korean
central laboratory, the conversion rates were obtained
with Passing and Bablok regression method. With revised
HDL-C formula, bias was in range of 0.17 to 0.84 mg/dL.
Samples in 2012 were verified in similar manner by Abell-
Kendall method.
 Revised HDL-C (2010-2011) 5 0.872! HDL-C (2010-
2011) 1 6.162
 Revised HDL-C (2012) 5 0.952 ! HDL-C
(2012) 1 1.096
The definition of low HDL-C followed the criteria
proposed by NCEP ATP III5: ,40 mg/dL in men and
,50 mg/dL in women. The cutoff for TGs and LDL-C
were set at 200 and 160 mg/dL, respectively. CVA was
determined when a subject was ever told that they had a
stroke by a health care professional, and IHD was deter-
mined when a subject was ever told that they had coronary
heart disease, angina, or a heart attack by a health care pro-
fessional. Diabetes mellitus status was classified as follows:
normal glucose tolerance (fasting glucose, ,100 mg/dL),
impaired fasting glucose (fasting glucose, $100 and
,126 mg/dL), and diabetes mellitus (fasting glucose,
$126 mg/dL, HbA1C$ 6.5%, taking oral diabetic medica-
tion, or taking insulin). Subjects with systolic blood pres-
sure of $140 mm Hg, with diastolic blood pressure of
$90 mm Hg, or taking antihypertensive medication were
classified as hypertensive. Subjects who ever smoked
,100 cigarettes were considered nonsmokers, and subjects
who ceased smoking but smoked .100 cigarettes in the
past were considered ex-smokers.
Statistical analyses
All statistical analyses were performed using a complex
sample design using SPSS version 20.0 (IBM Co,
Armonk, NY, USA). Stratification variables and sampling
weights were used as designated in KNHANES and
NHANES. The total sum of weights of KNHANES and
NHANES were adjusted to be the same in each population
for comparability. A general linear model, adjusted for
age, was used to compare HDL-C levels between the
surveys according to TG level, LDL-C level, hypertension,
diabetes, and smoking status. To estimate the performance
of each HDL-C cutoff value for predicting the risk of CVA
and IHD, the odds ratio (OR), sensitivity, and specificity
were calculated ranging from 35 to 60 mg/dL at 1 mg/dL
intervals. The optimal cutoff value of HDL-C was







. For that ana-
lysis, subjects taking dyslipidemia medication or supple-
ments were excluded.
All data are presented as mean (SE) for continuous
variables and percentage (SE) for nominal variables. Sta-
tistical significance was defined as P , .05.Results
Baseline characteristics and distribution of
HDL-C in KNHANES and NHANES
The analysis included 15,074 and 4033 subjects from
KNHANES V and NHANES 2011-2012, respectively.
The subjects in KNHANES (50.5 [0.2] years) were
significantly younger than those in NHANES (52.7 [0.5]
years; P , .001). They also had a significantly lower BMI
(P , .001) and waist circumference (P , .001) than those
in NHANES (Table 1). The prevalence of hypertension and
diabetes were significantly lower in KNHANES (P , .001
and P 5 .010, respectively). Either CVA or IHD (CVA-
IHD) also occurred less frequently in the subjects in
KNHANES compared with those in NHANES (P , .001;
Table 1). In terms of lipid profile, subjects in KNHANES
showed a significantly higher LDL-C level (P , .001).
Men in KNHANES had a higher TG level than men in
NHANES (P 5 .011). Mean HDL-C was significantly
lower in KNHANES than in NHANES in both sexes
(46.1 [0.2] and 47.7 [0.5] mg/dL, respectively, P 5 .003
in men; 51.2 [0.2] and 58.3 [0.8] mg/dL, respectively,
P , .001 in women; Table 1 and Supplementary Fig. 1).
Based on the conventional NCEP ATP III criteria, 31.1%
and 49.2% of Korean men and women, respectively, had
low HDL-C, whereas 26.5% and 29.1% of US men and
women, respectively, had low HDL-C. We subsequently
estimated the proportion of subjects with variable HDL-C
cutoff ranging from 35 to 60 mg/dL (Supplemental
Table 1). The proportion of Korean women with HDL-C
of #45 mg/dL was 31.3%, which was still higher than
the proportion of US women with HDL-C of #50 mg/dL
(Supplemental Table 1).
HDL-C was significantly lower in the subjects with a
history of CVA-IHD in both sexes in both KNHANES and
NHANES. In men in KNHANES, the mean HDL-C was
42.8 (0.7) mg/dL with CVA-IHD and 46.1 (0.2) mg/dL
without CVA-IHD. In men in NHANES, the mean HDL-C
was 46.3 (1.6) mg/dL with CVA-IHD and 47.9 (0.5) mg/dL
without CVA-IHD (Table 2). The same trends were evident
in women (Table 3). To reduce the confounder to clarify
whether there is difference in reference level of HDL-C be-
tween KNHANES and NHANES, the HDL-C levels were
compared between the surveys for each age group of sub-
jects without CVA-IHD. Comparing HDL-C level between
KNHANES and NHANES in each age group, the HDL-C
levels in Korean women were lower than those in US
women across all age groups (Table 3 and Supplementary
Fig. 2). In men, significantly lower HDL-C levels were
observed in Korean men only in the 60- to 69-year and
70- to 79-year groups (Table 2).
In both men and women in NHANES, HDL-C levels
increased with increasing age (P for trend , .001 in men
and P for trend 5 .004 in women; Tables 2 and 3). The
relationship between age and HDL-C was the opposite in
Table 1 The baseline characteristics of KNHANES and NHANES subjects
Characteristics KNHANES (2010-2012) N 5 15,074 NHANES (2011-2012) N 5 4033 P value
Weighted N 8.67 ! 107 8.95 ! 107
Demographics
Age, y 50.5 (0.2) 52.7 (0.5) ,.001
Gender (male), % 48.9 (0.3) 47.6 (1.0) .210
Current smoker, % 25.6 (0.5) 19.3 (1.0) ,.001
Hypertension, % 28.9 (0.9) 37.6 (1.1) ,.001
Diabetes mellitus, % 10.2 (0.3) 12.0 (0.6) .010
Lipid medication, % 5.8 (0.2) 21.8 (1.2) ,.001
Anthropometric measures
Body weight, kg 63.7 (0.1) 81.6 (0.6) ,.001
Body mass index, kg/m2 23.9 (0.0) 28.7 (0.2) ,.001
Waist circumference, cm 82.1 (0.1) 94.8 (0.7) ,.001
SBP, mm Hg 120.3 (0.2) 121.6 (0.8) .093
DBP, mm Hg 77.4 (0.1) 71.0 (0.5) ,.001
Lipid profiles
Total cholesterol, mg/dL 191.9 (0.4) 199.5 (1.1) ,.001
HDL-C, mg/dL 48.6 (0.1) 53.2 (0.5) ,.001
Male 46.1 (0.2) 47.7 (0.5) .003
Female 51.2 (0.2) 58.3 (0.8) ,.001
Non–HDL-C, mg/dL 143.4 (0.4) 146.3 (1.0) .011
Male 145.2 (0.6) 146.8 (1.0) .023
Female 141.6 (0.5) 145.8 (1.2) .014
TG, mg/dL 142.1 (1.4) 131.5 (4.5) .023
Male 165.4 (2.1) 147.3 (6.7) .011
Female 119.3 (1.4) 116.6 (3.9) .518
LDL-C, mg/dL 117.2 (0.7) 110.1 (1.7) ,.001
Cardiovascular disease
CVA-IHD, % 4.2 (0.2) 9.2 (0.2) ,.001
CVA, % 1.6 (0.1) 3.5 (0.4) ,.001
IHD, % 2.6 (0.2) 6.6 (0.4) ,.001
CVA, cerebrovascular accident; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; IHD, ischemic heart disease; KNHANES,
Korean National Health and Nutrition Examination Survey; LDL-C, low-density lipoprotein cholesterol; NHANES, National Health and Nutrition
Examination Survey; SBP, systolic blood pressure; TG, triglyceride.
Values are presented as mean or % (standard error).
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were significantly lower than NHANES across all age
groups. Subgroup analysis for menopause revealed that
Korean women had lower HDL-C levels after menopause
(P 5 .004, adjusted for age), which was not found in US
women (P5 .272, adjusted for age; Table 3). Of the Korean
women, 8.2% were taking hormone replacement therapy
(HRT) compared with 22.9% of US women. Excluding
women taking HRT, Korean women continued to have
lower HDL-C levels after menopause (P 5 .021, adjusted
for age), whereas US women did not (P 5 .185, adjusted
for age). In postmenopausal women, HDL-C decreased
after excluding HRT in both populations (Korean,
49.8-49.6 mg/dL; US, 59.5-58.5 mg/dL). The association
between age and HDL-C levels was not significant in
Korean men.
Hypertriglyceridemia, hypertension, and diabetes affec-
ted HDL-C levels in both KNHANES and NHANES,although smoking status did not (Tables 2 and 3). As it is
well-known that HDL-C is closely correlated with TGs,21
we compared HDL-C only in the subjects with TG level
of ,200 mg/dL. In Korean men and women with TG level
of ,200 mg/dL, mean HDL-C was 47.9 (0.2) and 52.4
(0.2) mg/dL, respectively, which was significantly lower
than that in US men and women with TG level of
,200 mg/dL who had mean HDL-C levels of 50.4 (0.8)
mg/dL (P 5 .003) and 60.6 (1.1) mg/dL, respectively
(P , .001; Tables 2 and 3). Irrespective of the absence
or presence of hypertension, subjects in NHANES
showed significantly higher HDL-C levels than those in
KNHANES. In subjects with diabetes, there was no differ-
ence in HDL-C levels between KNHANES and NHANES
in both sexes, although the subjects with normal glucose
tolerance or impaired fasting glucose in KNHANES
showed significantly lower HDL-C levels than those in
NHANES (Tables 2 and 3).
Table 2 The distribution of high-density lipoprotein cholesterol (HDL-C) by associated variables in men
Variables
KNHANES NHANES
P value‡Total CVA-IHD(2) CVA-IHD(1) P value* P value† Total CVA-IHD(2) CVA-IHD(1) P value* P value†
Total 46.1 (0.2) 46.1 (0.2) 42.8 (0.7) ,.001 47.7 (0.5) 47.9 (0.5) 46.3 (1.6) .032 .005
Age, y
30-39 46.4 (0.4) 46.5 (0.4) 45.1 (1.3) .587 .725 46.7 (0.7) 46.7 (0.6) 46.0 (7.7) .923 ,.001 .756
40-49 45.7 (0.3) 45.6 (0.3) 41.7 (0.3) .043 45.9 (0.6) 46.1 (0.5) 41.9 (2.9) .153 .726
50-59 46.0 (0.4) 46.2 (0.4) 41.0 (1.5) .002 46.8 (1.0) 46.8 (1.0) 47.0 (2.9) .936 .428
60-69 46.1 (0.4) 46.4 (0.4) 43.6 (0.9) .008 51.1 (1.4) 51.5 (1.5) 49.2 (2.4) .343 .001
701 46.2 (0.4) 46.6 (0.5) 43.5 (1.0) .007 49.8 (1.2) 52.2 (1.0) 45.1 (2.2) .002 .004
Smoking
Nonsmoker 45.9 (0.4) 46.0 (0.4) 43.6 (1.6) .137 .439 46.9 (0.8) 46.9 (0.7) 46.5 (3.0) .389 .362 .267
Ex-smoker 46.4 (0.3) 46.6 (0.3) 43.4 (0.9) .001 48.5 (0.7) 49.0 (0.9) 45.6 (1.2) .003 .006
Current smoker 45.7 (0.3) 45.9 (0.3) 41.3 (1.1) ,.001 48.1 (1.2) 48.3 (1.1) 47.2 (2.7) .468 .041
TG
,200 47.8 (0.2) 47.9 (0.2) 44.2 (0.7) ,.001 ,.001 50.1 (0.8) 50.4 (0.8) 48.1 (2.3) .141 ,.001 .003
$200 40.7 (0.3) 40.8 (0.3) 37.0 (1.0) ,.001 38.8 (0.8) 39.1 (1.0) 37.2 (1.4) .322 .025
LDL-C
,160 44.6 (0.3) 44.8 (0.3) 41.5 (1.1) .006 .638 48.6 (0.7) 49.0 (0.7) 46.4 (2.1) .093 .872 ,.001
$160 44.3 (0.7) 44.4 (0.7) 33.8 (2.1) ,.001 48.1 (1.2) 48.5 (1.2) 43.5 (3.9) .244 .007
Hypertension
No 45.7 (0.4) 45.9 (0.4) 44.9 (0.6) .014 .192 47.5 (0.6) 47.5 (0.6) 48.1 (2.8) .581 .454 .010
Yes 44.6 (0.5) 40.5 (2.1) 40.8 (1.2) .005 47.9 (0.6) 48.4 (0.7) 45.6 (1.7) .026 ,.001
Diabetes
NGT 46.5 (0.2) 46.6 (0.2) 42.9 (0.9) ,.001 ,.001 49.3 (0.9) 49.1 (0.9) 52.2 (4.2) .930 ,.001 .006
IFG 45.6 (0.3) 45.6 (0.3) 42.1 (1.0) ,.001 48.8 (1.0) 49.1 (1.1) 47.0 (2.7) .210 .003
DM 43.8 (0.5) 43.9 (0.6) 43.9 (1.7) .904 43.0 (0.8) 43.8 (1.0) 40.3 (1.6) .023 .647
Lipid medication
No 46.1 (0.2) 46.2 (0.2) 45.3 (0.8) ,.001 .291 47.9 (0.5) 47.9 (0.6) 48.5 (2.9) .573 .017 .005
Yes 44.4 (0.7) 44.7 (0.5) 43.1 (1.0) .001 46.8 (0.7) 47.5 (0.8) 45.1 (1.6) .103 .044
CVA, cerebrovascular accident; DM, diabetes mellitus; IFG, impaired fasting glucose; IHD, ischemic heart disease; KNHANES, Korean National Health and Nutrition Examination Survey; LDL-C, low-density
lipoprotein cholesterol; NGT, normal glucose tolerance; NHANES, National Health and Nutrition Examination Survey; TG, triglyceride.
Values are presented as mean (standard error) HDL-C in units of mg/dL.
*Comparing HDL-C between CVA-IHD(2) and CVA-IHD(1) in the same subgroup of a variable (adjusted for age).
†Comparing HDL-C according to each factor in subjects without CVA-IHD (adjusted for age); P for trend for age, smoking, and diabetes (adjusted for age).


































Table 3 The distribution of high-density lipoprotein cholesterol (HDL-C) by associated variables in women
Variables
KNHANES NHANES
P value‡Total CVA-IHD(2) CVA-IHD(1) P value* P value† Total CVA-IHD(2) CVA-IHD(1) P value* P value†
Total 51.2 (0.2) 51.3 (0.2) 47.6 (0.7) .042 58.3 (0.8) 58.8 (0.8) 52.7 (1.0) ,.001 ,.001
Age, y
30-39 53.9 (0.3) 53.8 (0.3) 56.3 (3.1) .434 ,.001 56.2 (1.1) 56.2 (1.1) 55.3 (7.7) .902 .004 .037
40-49 51.7 (0.3) 51.8 (0.3) 46.1 (2.7) .035 56.3 (0.8) 56.6 (0.8) 48.3 (3.5) .029 ,.001
50-59 51.1 (0.3) 51.1 (0.3) 51.2 (1.8) .993 60.3 (1.8) 60.8 (1.9) 49.7 (2.0) .001 ,.001
60-69 49.1 (0.4) 49.0 (0.3) 48.5 (1.4) .720 60.5 (1.7) 61.3 (1.9) 52.8 (2.0) .022 ,.001
701 46.8 (0.3) 47.2 (0.3) 44.4 (0.9) .004 59.0 (1.2) 60.5 (1.4) 54.3 (1.8) .013 ,.001
Smoking
Nonsmoker 51.0 (0.2) 51.2 (0.2) 47.7 (0.7) .042 .285 58.3 (0.7) 58.5 (0.7) 54.7 (1.8) .050 .723 ,.001
Ex-smoker 52.6 (0.9) 53.0 (0.9) 43.3 (3.6) .105 60.1 (1.2) 61.1 (1.4) 51.1 (2.4) .001 ,.001
Current smoker 52.2 (0.8) 52.3 (0.9) 49.4 (7.3) .816 55.7 (1.5) 56.3 (1.6) 50.5 (1.9) .004 .046
Menopause
No 52.5 (0.2) 52.5 (0.2) 50.8 (2.0) .513 56.2 (1.0) 56.3 (1.0) 53.3 (3.7) .429 ,.001
Yes 49.8 (0.2) 50.0 (0.2) 47.1 (0.8) .069 .004 59.5 (1.2) 60.5 (1.3) 52.5 (1.2) ,.001 .272 ,.001
Yes (no HRT) 49.6 (0.2) 49.8 (0.2) 46.8 (0.8) .054 .021 58.5 (1.1) 59.2 (1.2) 53.2 (1.5) .004 .185 ,.001
TG
,200 52.6 (0.2) 52.4 (0.2) 49.4 (0.7) .215 ,.001 60.3 (1.1) 60.6 (1.1) 57.9 (1.8) .002 ,.001 ,.001
$200 42.4 (0.4) 42.7 (0.4) 39.0 (1.2) .019 45.4 (1.3) 46.3 (1.4) 39.3 (1.4) .075 .025
LDL-C
,160 49.2 (0.3) 49.3 (0.3) 45.7 (1.3) .396 .002 58.8 (1.1) 59.0 (1.1) 56.5 (1.6) .010 .211 ,.001
$160 50.8 (0.8) 51.1 (0.8) 41.5 (3.2) .006 61.6 (2.0) 62.0 (2.2) 54.0 (5.0) .117 ,.001
Hypertension
No 51.5 (0.3) 51.6 (0.3) 47.8 (0.5) .213 .047 59.1 (0.9) 59.2 (0.9) 52.8 (2.9) .013 .002 ,.001
Yes 47.9 (0.5) 47.3 (2.1) 48.8 (1.9) .446 57.2 (0.9) 58.0 (1.2) 52.7 (1.4) .005 ,.001
Diabetes
NGT 52.1 (0.2) 52.2 (0.2) 48.1 (1.0) .066 ,.001 61.5 (1.0) 62.0 (0.9) 53.9 (2.2) .001 ,.001 ,.001
IFG 49.1 (0.4) 49.2 (0.4) 47.5 (1.4) .641 59.5 (1.4) 59.2 (1.4) 63.3 (3.2) .791 ,.001
DM 45.0 (0.6) 45.1 (0.6) 45.3 (1.8) .763 47.8 (1.0) 47.7 (1.3) 48.4 (2.7) .550 .060
Lipid medication
No 51.3 (0.2) 51.4 (0.2) 47.8 (0.8) .169 .738 58.8 (0.7) 58.9 (0.8) 56.2 (2.1) .042 .015 ,.001
Yes 49.0 (0.5) 49.4 (0.6) 46.9 (1.3) .097 56.4 (1.2) 58.1 (1.5) 50.5 (1.2) .003 ,.001
CVA, cerebrovascular accident; DM, diabetes mellitus; HRT, hormone replacement therapy; IFG, impaired fasting glucose; IHD, ischemic heart disease; KNHANES, Korean National Health and Nutrition
Examination Survey; LDL-C, low-density lipoprotein cholesterol; NGT, normal glucose tolerance; NHANES, National Health and Nutrition Examination Survey; TG, triglyceride.
Values are presented as mean (standard error) HDL-C in units of mg/dL.
*Comparing HDL-C between CVA-IHD(2) and CVA-IHD(1) in the same subgroup of a variable (adjusted for age).
†Comparing HDL-C according to each factor in subjects without CVA-IHD (adjusted for age); P for trend for age, smoking, and diabetes (adjusted for age).


























Figure 1 High-density lipoprotein cholesterol (HDL-C) cutoffs
to predict cerebrovascular accidents (CVA) and ischemic heart
disease (IHD) in the Korean population. The ability of identifying
the risk of CVA-IHD using different cutoff values of HDL-C.
KNHANES, Korean National Health and Nutrition Examination
Survey; NHANES, National Health and Nutrition Examination
Survey.
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Considering the difference in HDL-C in subjects without
CVA-IHD between KNHANES and NHANES, we inves-
tigated the optimal HDL-C cutoff values to predict CVA
and IHD using the Euclidean method. The minimal r values
for the prediction of CVA-IHD were 0.605 and 0.609 for
Korean men and women, respectively, which corresponded
to HDL-C levels of 43 mg/dL in men and 48 mg/dL in
women (Fig. 1). Sensitivity and specificity of each
HDL-C cutoff value were 58.2% and 56.2%, respectively,
in Korean men and 56.8% and 57.1%, respectively, in
Korean women. The ORs of the optimal HDL-C cutoff
values to predict CVA-IHD were 1.78 (95% confidence
interval [CI], 1.35-2.36) in Korean men and 1.75 (CI,
1.33-2.30) in Korean women. In US men and women, the
minimal r values were 0.661 and 0.611, respectively, which
corresponded to HDL-C levels of 41 and 56 mg/dL, respec-
tively. Sensitivity and specificity of the HDL-C cutoff
values were 41.0% and 70.3%, respectively, in US men,
and 61.0% and 53.0%, respectively, in US women. The
ORs of the optimal HDL-C cutoff values to predict
CVA-IHD were 1.65 (CI, 0.88-3.10) in US men and 1.76
(CI, 0.96-3.05) in US women. Subgroup analysis for sub-
jects with TG level of ,200 mg/dL and without diabetes
did not alter the optimal HDL-C cutoffs (data not shown).We subsequently investigated the separate HDL-C
cutoff values for CVA and IHD. The HDL-C cutoffs to
predict CVA were 43 mg/dL (OR, 2.09; CI, 1.40-3.12) and
47 mg/dL (OR, 2.10; CI, 1.30-3.40) for Korean men and
women, respectively, and 41 mg/dL (OR, 2.87; CI, 1.28-
6.45) and 56 mg/dL (OR, 1.41; CI, 0.65-6.05) for US men
and women, respectively. The HDL-C cutoffs for IHD were
43 mg/dL (OR, 1.58; CI, 1.10-2.27) and 49 mg/dL
(OR, 1.56; CI, 1.08-2.25) for Korean men and women,
respectively, and 47 mg/dL (OR, 1.38; CI, 0.75-2.52) and
56 mg/dL (OR, 1.78; CI, 0.72-4.39) for US men and
women, respectively.
Considering the difference of HDL-C between the
subjects with or without lipid medication, we analyzed
the optimal HDL-C cutoffs in the entire population in
predicting CVA-IHD. Including subjects taking lipid medi-
cation did not substantially alter HDL-C cutoffs except in
US men: it increased from 41 to 43 mg/dL in US men
(Supplementary Table 2).Discussion
Using nationwide data sets representing the Korean and
US populations, the present study confirmed that HDL-C
levels in the Korean population were significantly lower
than those in the US, by 1.6 mg/dL in men and 7.2 mg/dL
in women. These results support those of a previous study
that reported a higher prevalence of low HDL-C levels in
the Korean population than the US population.13 Further-
more, we estimated the optimal cutoff values for HDL-C
to predict the prevalence of CVA-IHD, which were
43 mg/dL for Korean men, 48 mg/dL for Korean women,
41 mg/dL for US men, and 56 mg/dL for US women.
Low HDL-C level is a well-known risk predictor for
stroke2 and IHD,3,4 although there has been little evidence
that modifying HDL-C level itself provides benefit.22 The
most frequently used definition of low HDL-C level is
based on the NCEP ATP III criteria; however, this is an
arbitrary value, and the panel agrees that reexamination
of the appropriate HDL-C cutoff is needed, as the associa-
tion between HDL-C and cardiovascular risk is continuous,
and inflection points are uncertain.5 Furthermore, the low
HDL-C cutoff in the NCEP ATP III definition of metabolic
syndrome is based on the HDL-C distribution in Cauca-
sians.6–8 Considering that ethnicity affects serum HDL-C
levels13,15 and that the definition of metabolic syndrome
is intended to identify individuals at cardiovascular risk,1
the determination of optimal HDL-C cutoff values specif-
ically for Asians is warranted.
Using the NCEP ATP III criteria, approximately 60% of
Korean women have been previously identified with low
HDL-C levels,13 which seems unreasonably high. In the
present study, the HDL-C levels in the Korean subjects
without CVA-IHD were even slightly lower than those
in the US subjects with a history of CVA-IHD. Especially
in women, the differences in HDL-C levels between
Moon et al HDL cholesterol cutoff for Koreans 341KNHANES and NHANES were considerable at all ages.
The present study analyzed data from a nationwide data-
base, and the estimated HDL-C cutoffs resulted in 44.2%
of men and 43.3% of women with low HDL-C levels.
Although we did not show a direct mechanism for the
difference in HDL-C levels between the Korean and US
populations, related factors can be inferred from previous
studies. Genetic polymorphisms in CETP,23 ABCA1,24
LIPC,25 and PPARg26 genes might explain the observed
ethnic difference in HDL-C level, ie, CETP 451Q allele,
which represents a significantly higher CETP activity and
lower HDL-C levels, has not been found in Asian popula-
tions.23 Along with genetic difference, environmental fac-
tors such as carbohydrate consumption can influence the
HDL-C level.27,28 Carbohydrates represent .70% of
energy intake for Korean adults owing to the high carbohy-
drate content of the Korean traditional diet; the US popula-
tion consumes less carbohydrates as a percentage of overall
energy intake.27,29 Further studies elucidating whether the
ethnic difference in HDL-C level belongs to genetic differ-
ence or environmental factors are required, which might
help to understand the clinical meaning of HDL-C level
among the difference populations.
Interestingly, the relationships between age and HDL-C
levels in women in the KNHANES and NHANES were
opposite. HDL-C levels decreased with increasing age in
Korean women and increased with increasing age in US
women. Endogenous estrogen levels might explain these
differences in HDL-C levels between the ethnic groups.
Decreased endogenous estrogen is thought to reduce
HDL-C, particularly subpopulation HDL2, by affecting
hepatic lipase activity.30 In contrast, increasing estrogen
levels through the administration of exogenous estrogen is
known to increase HDL-C levels.31 In the same vein, exclu-
sion of subjects with HRT resulted in decreased HDL-C in
postmenopausal women in both populations. In addition,
estrogen-receptor polymorphisms affect the degree of
HDL-C response to HRT.32 The prevalence of numerous
single-nucleotide polymorphisms on ESR1 and ESR2 has
been reported to differ by ethnicity.33 However, the effect
of estrogen receptor polymorphisms on HDL-C has not
been consistently reported; further independent studies
should be performed.
Regarding the presence of diabetes, there were no
differences in HDL-C levels between the Korean and US
subjects with diabetes, even after adjustment for age and
BMI. The main pathogenesis in diabetes is insulin resis-
tance, which also lowers HDL-C levels and increases TG
levels.34 It appears as if the effect of insulin resistance on
HDL-C is not affected by ethnic differences in HDL-C.
This study was performed using a nationwide survey,
which included a large number of subjects representing
each population. However, this study has certain limita-
tions. First, the cross-sectional analysis did not allow causal
relationships to be determined. Second, the questionnaires
were self-administered, which could have resulted in recall
bias. Third, differences in baseline characteristics includingage, body weight, and lipid profiles limited direct compar-
isons of HDL-C levels between the populations. However,
this did not affect the main purpose of this study, which was
to investigate the epidemiologic distribution of HDL-C and
the need for a different HDL-C cutoff value in the Korean
population. Furthermore, the stratified analysis that
accounted for confounders of HDL-C levels likely reduced
the risk of error when comparing the KNHANES and
NHANES data. However, the absolute r values, which were
calculated to evaluate HDL-C as a predictor for CVA and
IHD, were relatively high, with the majority at approxi-
mately 0.6. In addition, the sensitivity and specificity
were approximately 60%. High r values indicate that
HDL-C is not a good indicator for CVA or IHD as a single
parameter. Therefore, other metabolic risk factors, such as
age, body weight, other lipid indices, and genetic disposi-
tion, should also be considered in combination with
HDL-C when evaluating cardiovascular risk.
Based on nationwide survey data in the Korean and US
populations, HDL-C levels tended to be lower in Koreans,
and the differences were more pronounced in women. The
pattern of HDL-C levels through the life span varied by
population. Considering the different HDL-C distributions
by ethnicity, we suggest that lowerHDL-C cutoffs to evaluate
cardiovascular risk should be used for Korean women.
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